SEC Form 4 · accession 0001104659-17-047846
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott J Charles
Officer — Chief Financial Officer
Period of report
Jul 28, 2017
Accepted (ET)
Jul 28, 2017 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par value | Jul 28, 2017 | S | 10,804 | $1.2504 | D | 280,551 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 29,000 restricted stock units, which vested on July 27, 2017. 7,284 of such restricted stock units were previously granted on July 27, 2015 and 21,716 of such restricted stock units were previously granted on February 12, 2016.